Granulocyte-macrophage colony-stimulating factor: unrealized potential.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Granulocyte-macrophage colony-stimulating factor: unrealized potential.

Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Murphy MJ Jr, ed. Dayton, OH, AlphaMed Press, p. 3-20, 1991.. Unique Identifier : AIDSLINE ICDB/93689904
Bonnem EM; Schering-Plough International, Kenilworth, NJ

Abstract: GM-CSF entered the clinic only 4 yr ago, yet it has already demonstrated widespread efficacy and utility in a number of clinical settings. As a single agent, GM-CSF can reverse the neutropenia of myelodysplastic syndrome and aplastic anemia. GM-CSF can also enhance recovery from bone marrow transplantation and thus reduce the attendant morbidity of this procedure. GM-CSF may also enhance recruitment and harvest of peripheral stem cells and, thereby, significantly affect the ability to deliver intensive chemotherapy with or without BMT. Its greatest potential use appears to be in the amelioration of neutropenia following myelosuppressive therapy in numerous studies of both AIDS patients and cancer patients receiving chemotherapy. GM-GSF has demonstrated efficacy in ameliorating ANC nadirs, decreasing the duration of neutropenia, decreasing the attendant infections, and enhancing the ability to deliver full doses of myelosuppressive therapy. Doses in the range of 5-10 mg/kg are effective in these settings and have been very well tolerated. Many future areas remain to be explored. The ability of GM-CSF to cycle bone marrow is now being explored, as well as combination studies of GM-CSF + Epo, + IL-3, + G-CSF. Other future studies are expected to more fully explore the potential benefits of enhanced immune function stimulated by GM-CSF, including combination studies with monoclonal antibodies and further work in infectious disease states.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Anemia, Aplastic/THERAPY Bone Marrow Transplantation Granulocyte-Macrophage Colony-Stimulating Factor/*THERAPEUTIC USE Hematopoietic Cell Growth Factors/THERAPEUTIC USE Human Myelodysplastic Syndromes/COMPLICATIONS Neoplasms/COMPLICATIONS Neutropenia/COMPLICATIONS/THERAPY MEETING PAPER
930430
M9340816

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .